Abstracts tagged "IgG4 Related Disease"

Abstract Number: 0417 • ACR Convergence 2020
Different Immunophenotypes Characterized IgG4-Related Disease Clinical Phenotypes
Eduardo Martin-Nares¹, Janette Furuzawa-Carballeda¹, Ángel Alexis Priego-Ranero¹, Isela Chan-Campos¹, Gladys Sulikey Herrera-Noguera¹, Fidel López-Verdugo¹ and Gabriela Hernandez-Molina¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico
Background/Purpose: Patients with IgG4-related disease (IgG4-RD) can be classified in clinical phenotypes which differ in terms of demographics, clinical and serological features. Whether there are…
Abstract Number: 1480 • ACR Convergence 2020
Abatacept for the Treatment of IgG4-Related Disease
Mark Matza¹, Cory Perugino¹, Liam Harvey², Zachary Wallace³, Hang Liu⁴, Shiv Pillai⁵ and John H. Stone⁶, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Newton, MA, ⁴Massachusetts General Hospital, Cambridge, MA, ⁵Harvard Medical School, Cambridge, MA, ⁶Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: To assess the efficacy and safety of abatacept (ABA) for the treatment of IgG4-related disease (IgG4-RD). To date, there are no FDA-approved treatments available…
Abstract Number: 1619 • ACR Convergence 2020
Immunoglobulin G Subclass Ordering Patterns for IgG4-Related Disease at an Academic Medical Center
Lena Eder¹ and David Leverenz², ¹Duke University Hospital, Chapel Hill, NC, ²Duke University, DURHAM, NC
Background/Purpose: We have noticed an increasing number of serum IgG4 levels ordered over the last several years at our institution. This study was performed to…
Abstract Number: 1710 • 2019 ACR/ARP Annual Meeting
Chemokine and Cytokine Tear Profile of Patients with IgG4-Related Disease
Eduardo Martin-Nares¹, Luis Llorente ¹, Guadalupe Lima ¹, Diego Hernández-Ramírez ¹, Isela Chan-Campos ¹, Vanessa Saavedra-González ¹ and Gabriela Hernandez-Molina ¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: The lacrimal gland is frequently involved in both IgG4-related disease (IgG4-RD) and Sjögren’s syndrome (SS) and presents with swelling and/or dry eye symptoms. Although…
Abstract Number: 1711 • 2019 ACR/ARP Annual Meeting
Distinctive Imaging Features Between IgG4-Related Ophthalmic Disease and Graves’ Orbitopathy: A Comparative Study
Eduardo Martin-Nares¹, Oziel Amaya-Piña ², Rosa Delia Delgado Hernández ² and Gabriela Hernandez-Molina ¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Radiology and Molecular Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: IgG4-related ophthalmic disease (IgG4-ROD) may present as a cause of orbital myositis leading to proptosis and diplopia. This clinical scenario can be mistakenly diagnosed…
Abstract Number: 2821 • 2019 ACR/ARP Annual Meeting
Clonal Expansion of a Specific Subset of Cytotoxic CD4+T Cells and Tissue Apoptosis in Patients with IgG4-related Disease
Cory Perugino¹, Naoki Kaneko ², Jesper Kers ³, Takashi Maehara ², Hamid Mattoo ⁴, Hang Liu ⁵, Vinay Mahajan ⁵, Musie Ghebremichael ⁵, Hugues Allard-Chamard ⁵, Yesim Tuncay ⁵, Emanuel Della Torre ⁶, Zachary Wallace ¹, Lloyd Liang ¹, Sydney Montesi ⁷, John Stone ⁸ and Shiv Pillai ⁹, ¹Massachusetts General Hospital, Boston, ²Kyushu University, Fukuoka, Japan, ³University of Amsterdam, Amsterdam, Netherlands, ⁴Sanofi, Cambridge, ⁵Ragon Institute of MGH, MTI and Harvard, Cambridge, ⁶Hospital San Raffaele, milan, Italy, ⁷Massachusetts General Hospital, Boston, MA, ⁸Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁹Ragon Institude of MGH, MIT and Harvard, Charlestown, MA
Background/Purpose: In IgG4-related disease (IgG4-RD), both activated B cells and CD4+ cytotoxic T lymphocytes (CD4+CTLs) expand clonally, accumulate in tissues, likely recognize distinct epitopes on…
Abstract Number: 115 • 2019 ACR/ARP Annual Meeting
CD8+ Cytotoxic T Lymphocytes Are Clonally-expanded in IgG4-related Disease and Home to Affected Tissues
Cory Perugino¹, Naoki Kaneko ², Takashi Maehara ², Jesper Kers ³, Hang Liu ⁴, Vinay Mahajan ⁴, Yesim Tuncay ⁴, Zachary Wallace ¹, Lloyd Liang ¹, Sydney Montesi ⁵, John Stone ⁶ and Shiv Pillai ⁷, ¹Massachusetts General Hospital, Boston, ²Kyushu University, Fukuoka, Japan, ³University of Amsterdam, Amsterdam, Netherlands, ⁴Ragon Institute of MGH, MTI and Harvard, Cambridge, ⁵Massachusetts General Hospital, Boston, MA, ⁶Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁷Ragon Institude of MGH, MIT and Harvard, Charlestown, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic immune-mediated fibrotic disease often causing multi-organ involvement. We have previously reported the association of SLAMF7+ CD4+ cytotoxic T…
Abstract Number: 372 • 2019 ACR/ARP Annual Meeting
Periaortitis and Coronary Arteritis in IgG4-Related Disease: Eastern Mediterranean Experience
Gozde Kubra Yardımcı ¹, Alper Sarı ¹, Abdulsamet Erden ², Ertugrul Cagri Bolek ¹, Bayram Farisoğulları ¹, Levent Kilic ³, Berkan Armagan ⁴, Umut Kalyoncu ⁵, Tuncay Hazırolan ⁶, Ali İhsan Ertenli ¹ and Omer Karadag⁷, ¹Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, ²Ministry of Health Ankara City Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ³Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁴Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey., Ankara, Turkey, ⁵Hacettepe University Department of Rheumatology, Ankara, Turkey, ⁶Hacettepe University, Division of Radiology, Ankara, ⁷Hacettepe University Vasculitis Centre, Ankara, Turkey / Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Ankara, Turkey
Background/Purpose: Immunoglobulin G4-related disease (IgG4-RD) is an immune-mediated fibroinflammatory condition that may involve multiple organ systems. IgG4-RD can also lead to large vessel vasculitis and…
Abstract Number: 945 • 2019 ACR/ARP Annual Meeting
Comparison of Clinical Manifestations in IgG4 Related Disease Patients with/without Aortitis/Periaortitis and Periarteritis: A Prospective Cohort Study of 587 Patients with IgG4-RD Disease
Linyi Peng ¹, Wen Zhang ² and Panpan Zhang¹, ¹Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China (People's Republic), ²Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China (People's Republic)
Background/Purpose: We aimed to clarify the clinical features of IgG4-related disease (IgG4-RD) with/without aortitis/periaortitis and periarteritis (PAO/PA), and evaluate the treatment efficacy of patients with…
Abstract Number: 972 • 2019 ACR/ARP Annual Meeting
Disease Severity Is Linked to an Increase in Autoantibody Diversity in IgG4-related Disease
Hang Liu¹, Cory Perugino ², Musie Ghebremichael ¹, Zachary Wallace ², Sydney Montesi ³, John Stone ⁴ and Shiv Pillai ⁵, ¹Ragon Institute of MGH, MTI and Harvard, Cambridge, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁵Ragon Institude of MGH, MIT and Harvard, Charlestown, MA
Background/Purpose: The oligoclonal expansion in IgG4-related disease (IgG4-RD) of both plasmablasts and tissue-infiltrating CD4+ cytotoxic T lymphocytes, the identification of specific auto-antigens as B cell…
Abstract Number: 1708 • 2019 ACR/ARP Annual Meeting
Azathioprine and Glucocorticoid Combination Might Be a Good Treatment Option to Achieve Remission in Patients with IgG4-related Disease
Aydan Köken Avşar¹, Onay Gercik ², Gercek Can ³, Berrin Zengin ⁴, Sinem Burcu Kocaer ⁵, Atilla Okan Kılıç ⁶, Sadettin Uslu ⁷, Ali Karakaş ⁵, Merih Birlik ⁵, Servet Akar ⁸ and Fatos Onen ⁹, ¹Dokuz Eylul University School of Medicine, Rheumatology,, Türkiye, Izmir, Turkey, ²Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ³Dokuz Eylul University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Izmir, Turkey, ⁴Dokuz Eylul University School of Medicine, Rheumatology,, Turkey,Izmir, Izmir, Turkey, ⁵Division of Rheumatology, Dokuz Eylül University School of Medicine, İzmir, Turkey, Turkey,Izmir, Izmir, Turkey, ⁶Dokuz Eylul University School of Medicine, Internal Medıcıne, Turkey,Izmir, Izmir, Turkey, ⁷Division of Rheumatology, Dokuz Eylül University School of Medicine, İzmir, Turkey, Izmir, Turkey, ⁸Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ⁹Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey
Background/Purpose: IgG4-related disease is a recently recognised inflammatory disease of unkown etiology, often seen in men over the age of 50 and may affect many…
Abstract Number: 1709 • 2019 ACR/ARP Annual Meeting
Juvenile-Onset IgG4-Related Disease: A Systematic Review
Eduardo Martin-Nares¹, Talia Díaz-Prieto ², Enrique Faugier-Fuentes ², Luis A. Aparicio Vera ² and Gabriela Hernandez-Molina ¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Rheumatology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico
Background/Purpose: IgG4-related disease (IgG4-RD) presenting in the pediatric age is rare. Natural history and outcomes are not well defined. The aim of this study was…
Abstract Number: 138 • 2018 ACR/ARHP Annual Meeting
Distinct Roles of Tfh2, SLAMF7+ Tfh1 Cells and Th1 Cells in the Pathogenesis of IgG4-RD
Kazuhiko Higashioka¹, Masahiro Ayano¹, Yasutaka Kimoto², Hiroki Mitoma¹, Mitsuteru Akahoshi¹, Yojiro Arinobu¹, Koichi Akashi¹, Takahiko Horiuchi³ and Hiroaki Niro⁴, ¹Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ²Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan, ³Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ⁴Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose: IgG4-related disease (IgG4-RD) is a novel disease entity characterized by the infiltration of IgG4-secreting plasmablasts (PBs) and the generation of germinal centers in various…
Abstract Number: 370 • 2018 ACR/ARHP Annual Meeting
Rituximab in Idiopathic Retroperitoneal Fibrosis
Veronika Boyeva¹, Hatim Alabsi², Michael Seidman³, Ryan Paterson⁴, Jason Kur⁵, Silvia Chang⁶, Luke Chen⁷ and Mollie Carruthers⁵, ¹Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Department of Radiology, King Abdulaziz University, Jeddah, Saudi Arabia, ³Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴Department of Urology, University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁶Department of Radiology, University of British Columbia, Vancouver, BC, Canada, ⁷Department of Hematology, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Retroperitoneal fibrosis (RPF) is a rare disease characterized by the proliferation of fibrous tissue in the retroperitoneum, most commonly surrounding the aorta from the…
Abstract Number: 371 • 2018 ACR/ARHP Annual Meeting
Therapeutic Efficacy and Safety of Iguratimod in Treating Mild IgG4-Related Diseases
Wen Zhang¹ and Panpan Zhang², ¹Rheuamtology, Peking Union Medical College Hospital, Beijing, China, ²Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China
Background/Purpose: To evaluate the therapeutic efficacy and safety of Iguratimod in the treatment of mild IgG4 related disease (IgG4-RD). Methods: Thirty patients with newly diagnosed…

« Previous Page
1
…
5
6
7
8
9
…
11
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].